Skip to main content
Diasorin logo

Diasorin — Investor Relations & Filings

Ticker · DIA ISIN · IT0003492391 LEI · 8156002878BDF0EE4348 XMIL Manufacturing
Open in API
Filings indexed 817 across all filing types
Latest filing 2020-04-17 Regulatory Filings
Country IT Italy
Listing XMIL DIA

About Diasorin

https://diasoringroup.com/en

Diasorin is a global leader in the In Vitro Diagnostic (IVD) field, developing, producing, and marketing reagent kits for laboratory diagnostics. The company specializes in immunodiagnostics and molecular diagnostics. Its immunodiagnostics technology is based on detecting antibodies and antigens in fluid samples to identify diseases or measure physiological markers. The molecular diagnostics division provides flexible tools using targeted and multiplex technologies to detect pathogens in biological specimens. Since 2021, Diasorin has also been active in the Life Science business, offering platforms for biomedical research, clinical diagnostics, and drug discovery. Through its product lines, such as the LIAISON® family of analyzers and assays, the company aims to empower healthcare providers with actionable information to improve patient care, enable faster triage, and reduce unnecessary antibiotic use.

Recent filings

Filing Released Lang Actions
DIASORIN HAS CE MARKED ITS SARS-COV-2 IGG SEROLOGY KIT FOR COVID-19
Regulatory Filings Classification · 95% confidence The document is a formal announcement from DiaSorin dated April 17, 2020, regarding the CE marking of its SARS-CoV-2 IgG serology test kit. The metadata indicates it was received as 'REGEM' (likely a regulatory filing type in the source system) and the content is a press release detailing a significant business/product development (CE marking and FDA submission). It is not a full Annual Report (10-K), an Interim Report (IR), a Call Transcript (CT), or a specific financial filing like a Director's Dealing (DIRS) or Dividend Notice (DIV). It is a general, material announcement that doesn't fit the highly specific financial report categories. Given the nature of the announcement (a product milestone/regulatory clearance), and the lack of a specific category for product news or general corporate updates outside of management changes or financial results, the most appropriate fallback category is Regulatory Filings (RNS), as it is a formal regulatory/market-moving communication.
2020-04-17 English
DIASORIN HA MARCATO CE IL PROPRIO TEST SIEROLOGICO SARS-COV-2 IGG PER IL COVID-19
Regulatory Filings Classification · 95% confidence The document is an official communication from DiaSorin, identified by the header 'Informazione Regolamentata' (Regulated Information) and the filing type 'REGEM'. The subject is the CE marking of a new SARS-CoV-2 IgG serological test. This type of announcement, detailing a significant operational or product development milestone that is material to investors, fits best under a general regulatory announcement category, as it is not a standard financial report (10-K, IR, ER) or a specific corporate action like a dividend or management change. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general, material regulatory disclosure that doesn't fit the other specific codes. The document length is moderate, but the content is a direct announcement, not a solicitation or a report publication announcement (RPA).
2020-04-17 Italian
Comunicato Internal Dealing
Director's Dealing Classification · 99% confidence The document header explicitly states the 'Oggetto' (Subject) as 'Comunicato Internal Dealing' (Internal Dealing Communication). Furthermore, the template title is 'Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.' This directly corresponds to the definition of Director's Dealing (insider trades by executives/directors). Therefore, the filing type is DIRS.
2020-04-16 Italian
Launch of IgG test to detect immune response to SARS-COV-2
Regulatory Filings Classification · 99% confidence The document is a formal announcement from DiaSorin, dated April 7, 2020, regarding the launch of a new serology test for SARS-CoV-2 antibodies. The metadata indicates it was received as 'REGEM' (Regulated Information) and contains an 'Oggetto' (Subject) line typical of regulatory disclosures. The content describes a significant business development (product launch) and includes quotes from management. This type of announcement, detailing a major operational or product event that is material to investors, is generally classified as a general Regulatory Filing (RNS) if it doesn't fit a more specific category like Earnings Release (ER) or Capital Update (CAP). Since it is not a full financial report (10-K, IR), a transcript (CT), or a management discussion (MDA), RNS is the most appropriate general regulatory disclosure category for this type of news release.
2020-04-07 English
Lancio test IgG per identificare risposta immunitaria al SARS-COV-2
Regulatory Filings Classification · 98% confidence The document is a formal announcement dated April 7, 2020, from DiaSorin, detailing the launch of a new automated serological test for identifying the immune response to SARS-CoV-2. The structure, including metadata fields like 'Informazione Regolamentata' and 'Oggetto' (Subject: Launch of IgG test to identify immune response to SARS-COV-2), strongly suggests a regulatory disclosure or press release regarding a significant business/product development. Since it is an announcement about a product launch and related regulatory steps (CE mark, FDA EUA), and not a comprehensive financial report (10-K, IR), an earnings release (ER), or a transcript (CT), it fits best under the general category for regulatory announcements that are not otherwise specified. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a significant, non-financial, non-meeting-related corporate announcement, although 'Capital/Financing Update' (CAP) or 'Management Reports' (MDA) are less likely fits. Since it is a formal, regulated communication about a product/development, RNS serves as the best general regulatory disclosure category when specific product/legal/management codes do not apply perfectly. The document length (5836 chars) is substantial enough that it is the report itself, not just a notice of publication (RPA).
2020-04-07 Italian
Update Annual Calendar of Corporate Events 2020
Report Publication Announcement Classification · 99% confidence The document is titled 'Update Annual Calendar of Corporate Events 2020' and lists future dates for Board of Directors meetings (for results approval) and the Shareholders' Meeting. It is a formal announcement detailing the schedule of upcoming corporate actions and reporting deadlines, rather than the reports themselves (like 10-K or IR) or a transcript (CT). Since it is an announcement about future corporate events and reporting schedules, it fits best under the general category of Regulatory Filings (RNS) as a formal notice, although it is highly specific. Given the options, it is not a specific financial report, management change, dividend notice, or AGM material itself, but a schedule announcement. It is a formal regulatory communication regarding corporate governance and reporting timelines. RNS is the most appropriate fallback for specific, non-standard regulatory updates.
2020-03-26 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.